<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Doklady Biological Sciences</journal-id><journal-title-group><journal-title xml:lang="en">Doklady Biological Sciences</journal-title><trans-title-group xml:lang="ru"><trans-title>Доклады Российской академии наук. Науки о жизни</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2686-7389</issn><issn publication-format="electronic">3034-5057</issn><publisher><publisher-name xml:lang="en">The Russian Academy of Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">697715</article-id><article-id pub-id-type="doi">10.7868/S3034543X25050114</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">A SYNGENIC MOUSE MODEL OF BREAST CANCER EXPRESSING HUMAN <italic>ERBB2</italic> AND <italic>NANOLUC</italic> LUCIFERASE GENES</article-title><trans-title-group xml:lang="ru"><trans-title>СИНГЕННАЯ МЫШИНАЯ МОДЕЛЬ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ЭКСПРЕССИРУЮЩАЯ ГЕНЫ <italic>ERBB2</italic> ЧЕЛОВЕКА И ЛЮЦИФЕРАЗЫ <italic>NANOLUC</italic></trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Shramova</surname><given-names>E. I.</given-names></name><name xml:lang="ru"><surname>Шрамова</surname><given-names>Е. И.</given-names></name></name-alternatives><email>shramova.e.i@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Deyev</surname><given-names>S. M.</given-names></name><name xml:lang="ru"><surname>Деев</surname><given-names>С. М.</given-names></name></name-alternatives><bio xml:lang="en"><p>Academician of the RAS</p></bio><bio xml:lang="ru"><p>академик РАН</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Proshkina</surname><given-names>G. M.</given-names></name><name xml:lang="ru"><surname>Прошкина</surname><given-names>Г. М.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry RAS</institution></aff><aff><institution xml:lang="ru">Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Moscow Institute of Engineering Physics, National Research Nuclear University "MEPhI"</institution></aff><aff><institution xml:lang="ru">Московский инженерно-физический институт, Национальный исследовательский ядерный университет "МИФИ"</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Ogarev National Research Mordovian State University</institution></aff><aff><institution xml:lang="ru">Национальный исследовательский Мордовский государственный университет им. Н.П. Огарева</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-10-15" publication-format="electronic"><day>15</day><month>10</month><year>2025</year></pub-date><volume>524</volume><issue>1</issue><issue-title xml:lang="en">VOL 524, NO1 (2025)</issue-title><issue-title xml:lang="ru">ТОМ 524, №1 (2025)</issue-title><fpage>558</fpage><lpage>563</lpage><history><date date-type="received" iso-8601-date="2025-12-04"><day>04</day><month>12</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Russian Academy of Sciences</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Российская академия наук</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Russian Academy of Sciences</copyright-holder><copyright-holder xml:lang="ru">Российская академия наук</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2026-10-15"/></permissions><self-uri xlink:href="https://journals.eco-vector.com/2686-7389/article/view/697715">https://journals.eco-vector.com/2686-7389/article/view/697715</self-uri><abstract xml:lang="en"><p>Syngenetic models are widely used in experimental oncology both for modeling tumor diseases and for testing anticancer drugs. However, when testing targeted drugs aimed at human tumor-associated antigens, the presence of target antigens in the animal's body is important. In this work, a syngenetic cell line with stable expression of two genes — <italic>ERBB2</italic> gene encoding human epidermal growth factor type 2 <italic>HER2</italic>, and NaoLuc luciferase gene — was created based on human murine mammary gland carcinoma. Optical bioimaging methods have proven that the created cell line is characterized by stable expression of <italic>ERBB2</italic> and <italic>NanoLuc in vitro</italic> and <italic>in vivo</italic>, retains the aggressiveness growth of the original 4T1 cell line in animals, and forms spontaneous metastases that are detected in the animal's body by intravital biovisualization methods.</p></abstract><trans-abstract xml:lang="ru"><p>Сингенные модели широко применяются в экспериментальной онкологии как для моделирования опухолевого заболевания, так и для тестирования противораковых препаратов. Однако при тестировании таргетных препаратов, нацеленных на опухоль-ассоциированные антигены человека, важно наличие целевых антигенов в организме животного. В данной работе на основе мышиной карциномы молочной железы человека создана сингенная клеточная линия со стабильной экспрессией двух генов – гена <italic>ERBB2</italic>, кодирующего эпидермальный фактор роста человека второго типа <italic>HER2</italic>, и гена люциферазы NanoLuc. Методами оптического биоимиджинга доказано, что созданная клеточная линия характеризуется стабильной экспрессией <italic>ERBB2</italic> и <italic>NanoLuc in vitro</italic> и <italic>in vivo</italic>, сохраняет в животном агрессивность роста исходной клеточной линии 4T1 и образует спонтанные метастазы, которые детектируются в организме животного методами прижизненной биовизуализации.</p></trans-abstract><kwd-group xml:lang="en"><kwd>ERBB2</kwd><kwd>HER2</kwd><kwd>NanoLuc</kwd><kwd>tumor-associated antigen</kwd><kwd>optical bioimaging</kwd><kwd>syngenetic model</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>ERBB2</kwd><kwd>HER2</kwd><kwd>NanoLuc</kwd><kwd>опухоль-ассоциированный антиген</kwd><kwd>оптический биоимиджинг</kwd><kwd>сингенная модель</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена при поддержке гранта № 075-15-2024-536 (руководитель С.М. Деев) Министерства науки и высшего образования Российской Федерации.</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Иллюминовская Б. О., Шрамова Е. И., Пулас А. А., и др. Доставка барназы к клеткам в составе липосом, функционализированных HER2-специфичным модулем DARPin // Биоорг. химия. 2020. Т. 46. № 6. С. 701-707.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Шрамова Е. И., Прошкина Г. М., Деев С. М., и др. Фотоиндуцированная цитотоксичность флавопротеида miniSOG, вызванная биолюминесцентным резонансным переносом энергии, зависит от его внутриклеточной локализации // Доклады Академии наук. 2017. Т. 474. № 1. C. 633-636.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Marra A., Chandrarapaty S., Modi S. Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives // Nat. Rev. Clin. Oncol. 2024. V. 21. № 3. P. 185-202.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Waks A. G., Wiener E. P. Breast Cancer Treatment: A Review // JAMA. 2019. V. 321. № 3. P. 288-300.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Goldenberg M. M. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer // Clin. Ther. 1999. V. 21. № 2. P. 309-318.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Vu T., Slivkovski M. X., Claret F. Y. Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer // Biochim. Biophys. Acta. 2014. V. 1846. № 2. P. 353-365.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Xia L., Wen L., Qin Y., et al. HER2-targeted antibody-drug conjugate induces host immunity against cancer stem cells // Cell. Chem. Biol. 2021. V. 28. № 5. P. 610-624 e615.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Bakhtiarvand V. K., Akbari K. R., Sadri F., et al. Establishment of a murine model of breast cancer expressing human epidermal growth factor receptor 2 (4T1-HER2) // J. Cancer Res. Ther. 2024. V. 20. № 3. P. 984-992.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Taha Z., Crupi M. J. F., Allugmani N., et al. Syngene-ic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab entanisine combined with oncolytic rhabdovirus // Front. Immunol. 2023. V. 14. P. 1181014.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Li P., Yang L., Li T., et al. The Third Generation Anti-HER2 Chimeric Antigen Receptor Mouse T Cells Alone or Together With Anti-PD1 Antibody Inhibits the Growth of Mouse Breast Tumor Cells Expressing HER2 in vitro and in Immune Competent Mice // Front. Oncol. 2020. V. 10. P. 1143.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Sokolova E., Proshkina G., Kutova O., et al. Recombinant targeted toxin based on HER2-specific DARPin possesses a strong selective cytotoxic effect in vitro and a potent antitumor activity in vivo // J. Control. Release. 2016. V. 233. P. 48-56.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Shramova E. I., Frolova A. Y., Serova E. V., et al. A novel HER2-specific sensor based on DARPin. 9-29 and albumin binding domain for real-time fluorescence-guided tumor detection in animal model of cancer // Biochem. Biophys. Res. Commun. 2024. V. 734. P. 150747.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Dexter D. L., Kowalski H. M., Blazar B. A., et al. Heterogeneity of tumor cells from a single mouse mammary tumor // Cancer Res. 1978. V. 38. № 10. P. 3174-3181.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Pulaski B. A., Ostrand-Rosenberg S. Mouse 4T1 breast tumor model // Curr. Protoc. Immunol. 2001. V. Chapter 20. P. Unit 20 22.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Steiner D., Forrer P., Pluckthun A. Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display // J. Mol. Biol. 2008. V. 382. № 5. P. 1211-1227.</mixed-citation></ref></ref-list></back></article>
